Neuropeptide Y receptors: Ligand binding and trafficking suggest novel approaches in drug development

Journal of Peptide Science

Volumn 17, Issue 4, 2011, Pages 233-246

  Walther, Cornelia ^a   Mörl, Karin ^a   Beck Sickinger, Annette G ^a,b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Max Bergmann Society in Gotha   (Germany)

Author keywords

Drug development; GPCR; Internalization; NPY; Receptor trafficking; Structure activity relationship; YR

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIOBESITY AGENT; ANXIOLYTIC AGENT; GR 231118; LUAA 33810; MK 0557; N [1 (2 FLUOROPHENYL) 3 PYRAZOLYL] 3 OXOSPIRO(6 AZAISOBENZOFURAN 1(3H),1' CYCLOHEXANE) 4' CARBOXAMIDE; N [2 [1,2 DIHYDRO 3,5(4H) DIOXO 1,2 DIPHENYL 1,2,4 TRIAZOL 4 YL]ETHYL] N2 [[1 [2 [4 [5,11 DIHYDRO 6(6H) OXODIBENZ[B,E]AZEPIN 11 YL] 1 PIPERAZINYL] 2 OXOETHYL]CYCLOPENTYL]ACETYL]ARGININAMIDE; N [[4 [(4,5 DIHYDRO[1]BENZOTHIEPINO[5,4 D]THIAZOL 2 YL)AMINO]CYCLOHEXYL]METHYL]METHANESULFONAMIDE; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y RECEPTOR AGONIST; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; NEUROPEPTIDE Y4 RECEPTOR; NEUROPEPTIDE Y5 RECEPTOR; PANCREAS POLYPEPTIDE; PEPTIDE YY; UNCLASSIFIED DRUG;

ADRENAL CORTEX ADENOMA; BINDING AFFINITY; BLOOD BRAIN BARRIER; BRAIN TUMOR; BREAST CANCER; CANCER INHIBITION; DRUG DESIGN; EPILEPSY; HORMONE STRUCTURE; HUMAN; INTERNALIZATION; LIGAND BINDING; NEUROBLASTOMA; NEUROTRANSMISSION; NONHUMAN; OBESITY; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; PROTEIN TRANSPORT; REVIEW; SARCOMA; STRUCTURE ACTIVITY RELATION; TRANQUILIZING ACTIVITY;

DRUG DESIGN; HUMANS; LIGANDS; MOLECULAR STRUCTURE; NEOPLASMS; NEUROPEPTIDE Y; OBESITY; PANCREATIC POLYPEPTIDE; PEPTIDE YY; PROTEIN ISOFORMS; RECEPTORS, NEUROPEPTIDE Y;

EID: 79952466172     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1357     Document Type: Review

References (150)

1. Cabrele C, Beck-Sickinger AG. Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family. J. Pept. Sci. 2000; 6: 97-122.
2. Brothers SP, Wahlestedt C. Therapeutic potential of neuropeptide Y (NPY) receptor ligands. EMBO Mol. Med. 2010; 2: 429-439.
3. McDermott BJ, Bell D. NPY and cardiac diseases. Curr. Top. Med. Chem. 2007; 7: 1692-1703.
4. Ruscica M, Dozio E, Motta M, Magni P. Relevance of the neuropeptide Y system in the biology of cancer progression. Curr. Top. Med. Chem. 2007; 7: 1682-1691.
5. Serradeil-Le Gal C, Lafontan M, Raufaste D, Marchand J, Pouzet B, Casellas P, Pascal M, Maffrand JP, Le Fur G. Characterization of NPY receptors controlling lipolysis and leptin secretion in human adipocytes. FEBS Lett. 2000; 475: 150-156.
6. Haslam DW, James WP. Obesity. Lancet 2005; 366: 1197-1209.
7. Merten N, Beck-Sickinger AG. Molecular ligand-receptor interaction of the NPY/PP peptide family. EXS 2006; 35-62.
8. Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T, XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev. 1998; 50: 143-150.
9. Violin JD, Lefkowitz RJ. β-Arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol. Sci. 2007; 28: 416-422.
10. Rajagopal S, Rajagopal K, Lefkowitz RJ. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat. Rev. Drug Discov. 2010; 9: 373-386.
11. Blundell TL, Pitts JE, Tickle IJ, Wood SP, Wu CW. X-ray analysis (1.4-Å resolution) of avian pancreatic polypeptide: small globular protein hormone. Proc. Natl. Acad. Sci. U. S. A. 1981; 78: 4175-4179.
12. Lerch M, Mayrhofer M, Zerbe O. Structural similarities of micelle-bound peptide YY (PYY) and neuropeptide Y (NPY) are related to their affinity profiles at the Y receptors. J. Mol. Biol. 2004; 339: 1153-1168.
13. Monks SA, Karagianis G, Howlett GJ, Norton RS. Solution structure of human neuropeptide Y. J. Biomol. NMR 1996; 8: 379-390.
14. Bettio A, Beck-Sickinger AG. Biophysical methods to study ligand-receptor interactions of neuropeptide Y. Biopolymers 2001; 60: 420-437.
15. Bettio A, Dinger MC, Beck-Sickinger AG. The neuropeptide Y monomer in solution is not folded in the pancreatic-polypeptide fold. Protein Sci. 2002; 11: 1834-1844.
16. Kimmel JR, Hayden LJ, Pollock HG. Isolation and characterization of a new pancreatic polypeptide hormone. J. Biol. Chem. 1975; 250: 9369-9376.
17. Ekblad E, Sundler F. Distribution of pancreatic polypeptide and peptide YY. Peptides 2002; 23: 251-261.
18. Karra E, Batterham RL. The role of gut hormones in the regulation of body weight and energy homeostasis. Mol. Cell. Endocrinol. 2010; 316: 120-128.
19. Hazelwood RL. The pancreatic polypeptide (PP-fold) family: gastrointestinal, vascular, and feeding behavioral implications. Proc. Soc. Exp. Biol. Med. 1993; 202: 44-63.
20. Tatemoto K, Mutt V. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 1980; 285: 417-418.
21. Mentlein R, Dahms P, Grandt D, Krüger R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul. Pept. 1993; 49: 133-144.
22. Neary MT, Batterham RL. Peptide YY: food for thought. Physiol. Behav. 2009; 97: 616-619.
23. Karra E, Chandarana K, Batterham RL. The role of peptide YY in appetite regulation and obesity. J. Physiol. 2009; 587: 19-25.
24. Ueno H, Yamaguchi H, Mizuta M, Nakazato M. The role of PYY in feeding regulation. Regul. Pept. 2008; 145: 12-16.
25. McGowan BM, Bloom SR. Peptide YY and appetite control. Curr. Opin. Pharmacol. 2004; 4: 583-588.
26. Tatemoto K. Neuropeptide Y: complete amino acid sequence of the brain peptide. Proc. Natl. Acad. Sci. U. S. A. 1982; 79: 5485-5489.
27. Pedrazzini T, Pralong F, Grouzmann E. Neuropeptide Y: the universal soldier. Cell. Mol. Life Sci. 2003; 60: 350-377.
28. Minth CD, Bloom SR, Polak JM, Dixon JE. Cloning, characterization, and DNA sequence of a human cDNA encoding neuropeptide tyrosine. Proc. Natl. Acad. Sci. U. S. A. 1984; 81: 4577-4581.
29. Cerda-Reverter JM, Larhammar D. Neuropeptide Y family of peptides: structure, anatomical expression, function, and molecular evolution. Biochem. Cell. Biol. 2000; 78: 371-392.
30. Wahlestedt C, Yanaihara N, Håkanson R. Evidence for different pre- and post-junctional receptors for neuropeptide Y and related peptides. Regul. Pept. 1986; 13: 307-318.
31. Kalra SP, Kalra PS. NPY and cohorts in regulating appetite, obesity and metabolic syndrome: beneficial effects of gene therapy. Neuropeptides 2004; 38: 201-211.
32. Gehlert DR. Subtypes of receptors for neuropeptide Y: implications for the targeting of therapeutics. Life Sci. 1994; 55: 551-562.
33. Ekblad E, Edvinsson L, Wahlestedt C, Uddman R, Håkanson R, Sundler F. Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regul. Pept. 1984; 8: 225-235.
34. Brain SD, Cox HM. Neuropeptides and their receptors: innovative science providing novel therapeutic targets. Br. J. Pharmacol. 2006; 147: S202-S211.
35. Grundemar L, Håkanson R. Multiple neuropeptide Y receptors are involved in cardiovascular regulation. Peripheral and central mechanisms. Gen. Pharmacol. 1993; 24: 785-796.
36. Walker P, Grouzmann E, Burnier M, Waeber B. The role of neuropeptide Y in cardiovascular regulation. Trends Pharmacol. Sci. 1991; 12: 111-115.
37. Chee MJ, Colmers WF. Y eat? Nutrition 2008; 24: 869-877.
38. Hökfelt T, Stanic D, Sanford SD, Gatlin JC, Nilsson I, Paratcha G, Ledda F, Fetissov S, Lindfors C, Herzog H, Johansen JE, Ubink R, Pfenninger KH. NPY and its involvement in axon guidance, neurogenesis, and feeding. Nutrition 2008; 24: 860-868.
39. Thorsell A. Neuropeptide Y (NPY) in alcohol intake and dependence. Peptides 2007; 28: 480-483.
40. Thiele TE, Sparta DR, Hayes DM, Fee JR. A role for neuropeptide Y in neurobiological responses to ethanol and drugs of abuse. Neuropeptides 2004; 38: 235-243.
41. Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides 2004; 38: 213-224.
42. Morales-Medina JC, Dumont Y, Quirion R. A possible role of neuropeptide Y in depression and stress. Brain Res. 2010; 1314: 194-205.
43. Cleary J, Semotuk M, Levine AS. Effects of neuropeptide Y on short-term memory. Brain Res. 1994; 653: 210-214.
44. Lindner D, Stichel J, Beck-Sickinger AG. Molecular recognition of the NPY hormone family by their receptors. Nutrition 2008; 24: 907-917.
45. Dumont Y, Martel JC, Fournier A, St-Pierre S, Quirion R. Neuropeptide Y and neuropeptide Y receptor subtypes in brain and peripheral tissues. Prog. Neurobiol. 1992; 38: 125-167.
46. Hökfelt T, Brumovsky P, Shi T, Pedrazzini T, Villar M. NPY and pain as seen from the histochemical side. Peptides 2007; 28: 365-372.
47. Karl T, Herzog H. Behavioral profiling of NPY in aggression and neuropsychiatric diseases. Peptides 2007; 28: 326-333.
48. Wheway J, Herzog H, Mackay F. NPY and receptors in immune and inflammatory diseases. Curr. Top. Med. Chem. 2007; 7: 1743-1752.
49. Millar RP, Newton CL. The year in G protein-coupled receptor research. Mol. Endocrinol. 2010; 24: 261-274.
50. Wise A, Gearing K, Rees S. Target validation of G-protein coupled receptors. Drug Discov. Today 2002; 7: 235-246.
51. Fetissov SO, Kopp J, Hökfelt T. Distribution of NPY receptors in the hypothalamus. Neuropeptides 2004; 38: 175-188.
52. Herzog H, Hort YJ, Ball HJ, Hayes G, Shine J, Selbie LA. Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 5794-5798.
53. Castan I, Valet P, Larrouy D, Voisin T, Remaury A, Daviaud D, Laburthe M, Lafontan M. Distribution of PYY receptors in human fat cells: an antilipolytic system alongside the alpha 2-adrenergic system. Am. J. Physiol. 1993; 265: E74-E80.
54. Wahlestedt C, Håkanson R, Vaz CA, Zukowska-Grojec Z. Norepinephrine and neuropeptide Y: vasoconstrictor cooperation in vivo and in vitro. Am. J. Physiol. 1990; 258: R736-R742.
55. Wahlestedt C, Pich EM, Koob GF, Yee F, Heilig M. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science 1993; 259: 528-531.
56. Thiele TE, Koh MT, Pedrazzini T. Voluntary alcohol consumption is controlled via the neuropeptide Y Y1 receptor. J. Neurosci. 2002; 22: RC208.
57. Krause J, Eva C, Seeburg PH, Sprengel R. Neuropeptide Y1 subtype pharmacology of a recombinantly expressed neuropeptide receptor. Mol. Pharmacol. 1992; 41: 817-821.
58. Söll RM, Dinger MC, Lundell I, Larhammer D, Beck-Sickinger AG. Novel analogues of neuropeptide Y with a preference for the Y1-receptor. Eur. J. Biochem. 2001; 268: 2828-2837.
59. Mullins D, Kirby D, Hwa J, Guzzi M, Rivier J, Parker E. Identification of potent and selective neuropeptide Y Y(1) receptor agonists with orexigenic activity in vivo. Mol. Pharmacol. 2001; 60: 534-540.
60. Fuhlendorff J, Gether U, Aakerlund L, Langeland-Johansen N, Thøgersen H, Melberg SG, Olsen UB, Thastrup O, Schwartz TW. [Leu31, Pro34]neuropeptide Y: a specific Y1 receptor agonist. Proc. Natl. Acad. Sci. U. S. A. 1990; 87: 182-186.
61. Zwanziger D, Böhme I, Lindner D, Beck-Sickinger AG. First selective agonist of the neuropeptide Y1-receptor with reduced size. J. Pept. Sci. 2009; 15: 856-866.
62. Beck A, Jung G, Gaida W, Koppen H, Lang R, Schnorrenberg G. Highly potent and small neuropeptide Y agonist obtained by linking NPY 1-4 via spacer to alpha-helical NPY 25-36. FEBS Lett. 1989; 244: 119-122.
63. Cabrele C, Wieland HA, Koglin N, Stidsen C, Beck-Sickinger AG. Ala31-Aib32: identification of the key motif for high affinity and selectivity of neuropeptide Y at the Y5-receptor. Biochemistry 2002; 41: 8043-8049.
64. Parker EM, Balasubramaniam A, Guzzi M, Mullins DE, Salisbury BG, Sheriff S, Witten MB, Hwa JJ. [D-Trp(34)] neuropeptide Y is a potent and selective neuropeptide Y Y(5) receptor agonist with dramatic effects on food intake. Peptides 2000; 21: 393-399.
65. Cabrele C, Langer M, Bader R, Wieland HA, Doods HN, Zerbe O, Beck-Sickinger AG. The first selective agonist for the neuropeptide YY5 receptor increases food intake in rats. J. Biol. Chem. 2000; 275: 36043-36048.
66. Widdowson PS. Quantitative receptor autoradiography demonstrates a differential distribution of neuropeptide-Y Y1 and Y2 receptor subtypes in human and rat brain. Brain Res. 1993; 631: 27-38.
67. El Bahh B, Balosso S, Hamilton T, Herzog H, Beck-Sickinger AG, Sperk G, Gehlert DR, Vezzani A, Colmers WF. The anti-epileptic actions of neuropeptide Y in the hippocampus are mediated by Y and not Y receptors. Eur. J. Neurosci. 2005; 22: 1417-1430.
68. Schwartz TW. Pancreatic polypeptide: a hormone under vagal control. Gastroenterology 1983; 85: 1411-1425.
69. Lundell I, Blomqvist AG, Berglund MM, Schober DA, Johnson D, Statnick MA, Gadski RA, Gehlert DR, Larhammar D. Cloning of a human receptor of the NPY receptor family with high affinity for pancreatic polypeptide and peptide YY. J. Biol. Chem. 1995; 270: 29123-29128.
70. Ledeboer M, Masclee AA, Biemond I, Lamers CB. Gallbladder motility and cholecystokinin secretion during continuous enteral nutrition. Am. J. Gastroenterol. 1997; 92: 2274-2279.
71. Jain MR, Pu S, Kalra PS, Kalra SP. Evidence that stimulation of two modalities of pituitary luteinizing hormone release in ovarian steroid-primed ovariectomized rats may involve neuropeptide Y Y1 and Y4 receptors. Endocrinology 1999; 140: 5171-5177.
72. Bard JA, Walker MW, Branchek TA, Weinshank RL. Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y, and peptide YY. J. Biol. Chem. 1995; 270: 26762-26765.
73. Rodriguez M, Audinot V, Dromaint S, Macia C, Lamamy V, Beauverger P, Rique H, Imbert J, Nicolas JP, Boutin JA, Galizzi JP. Molecular identification of the long isoform of the human neuropeptide Y Y5 receptor and pharmacological comparison with the short Y5 receptor isoform. Biochem. J. 2003; 369: 667-673.
74. Gerald C, Walker MW, Criscione L, Gustafson EL, Batzl-Hartmann C, Smith KE, Vaysse P, Durkin MM, Laz TM, Linemeyer DL, Schaffhauser AO, Whitebread S, Hofbauer KG, Taber RI, Branchek TA, Weinshank RL. A receptor subtype involved in neuropeptide-Y-induced food intake. Nature 1996; 382: 168-171.
75. Guo H, Castro PA, Palmiter RD, Baraban SC. Y5 receptors mediate neuropeptide Y actions at excitatory synapses in area CA3 of the mouse hippocampus. J. Neurophysiol. 2002; 87: 558-566.
76. Cox HM. Neuropeptide Y receptors; antisecretory control of intestinal epithelial function. Auton. Neurosci. 2007; 133: 76-85.
77. Beck-Sickinger AG, Wieland HA, Wittneben H, Willim KD, Rudolf K, Jung G. Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations. Eur. J. Biochem. 1994; 225: 947-958.
78. 6.59 with C-terminal arginine residues in Y receptor ligands. J. Biol. Chem. 2007; 282: 7543-7551.
79. Sautel M, Rudolf K, Wittneben H, Herzog H, Martinez R, Munoz M, Eberlein W, Engel W, Walker P, Beck-Sickinger AG. Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor. Mol. Pharmacol. 1996; 50: 285-292.
80. Sjodin P, Holmberg SK, Akerberg H, Berglund MM, Mohell N, Larhammar D. Re-evaluation of receptor-ligand interactions of the human neuropeptide Y receptor Y1: a site-directed mutagenesis study. Biochem. J. 2006; 393: 161-169.
81. Akerberg H, Fallmar H, Sjodin P, Boukharta L, Gutierrez-de-Teran H, Lundell I, Mohell N, Larhammar D. Mutagenesis of human neuropeptide Y/peptide YY receptor Y2 reveals additional differences to Y1 in interactions with highly conserved ligand positions. Regul. Pept. 2010; 163: 120-129.
82. Lindner D, van Dieck J, Merten N, Mörl K, Gunther R, Hofmann HJ, Beck-Sickinger AG. GPC receptors and not ligands decide the binding mode in neuropeptide Y multireceptor/multiligand system. Biochemistry 2008; 47: 5905-5914.
83. Lindner D, Walther C, Tennemann A, Beck-Sickinger AG. Functional role of the extracellular N-terminal domain of neuropeptide Y subfamily receptors in membrane integration and agonist-stimulated internalization. Cell. Signal. 2009; 21: 61-68.
84. 1 receptor. J. Biol. Chem. 2002; 277: 6645-6655.
85. 2-adrenergic receptor. Nature 1996; 383: 447-450.
86. Calebiro D, Nikolaev VO, Persani L, Lohse MJ. Signaling by internalized G-protein-coupled receptors. Trends Pharmacol. Sci. 2010; 31: 221-228.
87. Pierce KL, Lefkowitz RJ. Classical and new roles of b-arrestins in the regulation of G-protein-coupled receptors. Nat. Rev. Neurosci. 2001; 2: 727-733.
88. Marchese A, Paing MM, Temple BR, Trejo J. G protein-coupled receptor sorting to endosomes and lysosomes. Annu. Rev. Pharmacol. Toxicol. 2008; 48: 601-629.
89. Luttrell LM, Lefkowitz RJ. The role of b-arrestins in the termination and transduction of G-protein-coupled receptor signals. J. Cell Sci. 2002; 115: 455-465.
90. Böhme I, Stichel J, Walther C, Mörl K, Beck-Sickinger AG. Agonist induced receptor internalization of neuropeptide Y receptor subtypes depends on third intracellular loop and C-terminus. Cell. Signal. 2008; 20: 1740-1749.
91. Parker SL, Parker MS, Lundell I, Balasubramaniam A, Buschauer A, Kane JK, Yalcin A, Berglund MM. Agonist internalization by cloned Y1 neuropeptide Y (NPY) receptor in Chinese hamster ovary cells shows strong preference for NPY, endosome-linked entry and fast receptor recycling. Regul. Pept. 2002; 107: 49-62.
92. Pheng LH, Dumont Y, Fournier A, Chabot JG, Beaudet A, Quirion R. Agonist- and antagonist-induced sequestration/internalization of neuropeptide Y Y1 receptors in HEK293 cells. Br. J. Pharmacol. 2003; 139: 695-704.
93. Fabry M, Langer M, Rothen-Rutishauser B, Wunderli-Allenspach H, Hocker H, Beck-Sickinger AG. Monitoring of the internalization of neuropeptide Y on neuroblastoma cell line SK-N-MC. Eur. J. Biochem. 2000; 267: 5631-5637.
94. Parker SL, Kane JK, Parker MS, Berglund MM, Lundell IA, Li MD. Cloned neuropeptide Y (NPY) Y1 and pancreatic polypeptide Y4 receptors expressed in Chinese hamster ovary cells show considerable agonist-driven internalization, in contrast to the NPY Y2 receptor. Eur. J. Biochem. 2001; 268: 877-886.
95. Berglund MM, Schober DA, Statnick MA, McDonald PH, Gehlert DR. The use of bioluminescence resonance energy transfer 2 to study neuropeptide Y receptor agonist-induced b-arrestin 2 interaction. J. Pharmacol. Exp. Ther. 2003; 306: 147-156.
96. Ouedraogo M, Lecat S, Rochdi MD, Hachet-Haas M, Matthes H, Gicquiaux H, Verrier S, Gaire M, Glasser N, Mely Y, Takeda K, Bouvier M, Galzi JL, Bucher B. Distinct motifs of neuropeptide Y receptors differentially regulate trafficking and desensitization. Traffic 2008; 9: 305-324.
97. Holliday ND, Lam CW, Tough IR, Cox HM. Role of the C terminus in neuropeptide YY1 receptor desensitization and internalization. Mol. Pharmacol. 2005; 67: 655-664.
98. Kilpatrick LE, Briddon SJ, Hill SJ, Holliday ND. Quantitative analysis of neuropeptide Y receptor association with β-arrestin2 measured by bimolecular fluorescence complementation. Br. J. Pharmacol. 2010; 160: 892-906.
99. Lecat S, Ouedraogo M, Cherrier T, Noulet F, Ronde P, Glasser N, Galzi JL, Mely Y, Takeda K, Bucher B. Contribution of a tyrosine-based motif to cellular trafficking of wild-type and truncated NPY Y(1) receptors. Cell. Signal. 2011; 23: 228-238.
100. Marion S, Oakley RH, Kim KM, Caron MG, Barak LS. A b-arrestin binding determinant common to the second intracellular loops of rhodopsin family G protein-coupled receptors. J. Biol. Chem. 2006; 281: 2932-2938.
101. Walther C, Nagel S, Gimenez LE, Mörl K, Gurevich VV, Beck-Sickinger AG. Ligand induced internalization and recycling of the human neuropeptide Y2 receptor is regulated by its Carboxyl-terminal tail. J. Biol. Chem. 2010; 285: 41578-41590.
102. Voisin T, Goumain M, Lorinet AM, Maoret JJ, Laburthe M. Functional and molecular properties of the human recombinant Y4 receptor: resistance to agonist-promoted desensitization. J. Pharmacol. Exp. Ther. 2000; 292: 638-646.
103. Parker SL, Parker MS, Buschauer A, Balasubramaniam A. Ligand internalization by cloned neuropeptide Y Y5 receptors excludes Y2 and Y4 receptor-selective peptides. Eur. J. Pharmacol. 2003; 474: 31-42.
104. Zwanziger D, Beck-Sickinger AG. Radiometal targeted tumor diagnosis and therapy with peptide hormones. Curr. Pharm. Des. 2008; 14: 2385-2400.
105. Daniels AJ, Matthews JE, Slepetis RJ, Jansen M, Viveros OH, Tadepalli A, Harrington W, Heyer D, Landavazo A, Leban JJ, Spaltenstein A. High-affinity neuropeptide Y receptor antagonists. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 9067-9071.
106. 4 receptors. Br. J. Pharmacol. 2000; 129: 37-46.
107. 2 (BW1911U90). J. Med. Chem. 2001; 44: 1479-1482.
108. Koglin N, Zorn C, Beumer R, Cabrele C, Bubert C, Sewald N, Reiser O, Beck-Sickinger AG. Analogues of neuropeptide Y containing b-aminocyclopropane carboxylic acids are the shortest linear peptides that are selective for the Y1 receptor. Angew. Chem. Int. Ed. Engl. 2003; 42: 202-205.
109. Rudolf K, Eberlein W, Engel W, Wieland HA, Willim KD, Entzeroth M, Wienen W, Beck-Sickinger AG, Doods HN. The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226. Eur. J. Pharmacol. 1994; 271: R11-R13.
110. Erondu N, Gantz I, Musser B, Suryawanshi S, Mallick M, Addy C, Cote J, Bray G, Fujioka K, Bays H, Hollander P, Sanabria-Bohorquez SM, Eng W, Långström B, Hargreaves RJ, Burns HD, Kanatani A, Fukami T, MacNeil DJ, Gottesdiener KM, Amatruda JM, Kaufman KD, Heymsfield SB. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell. Metab. 2006; 4: 275-282.
111. Walker MW, Wolinsky TD, Jubian V, Chandrasena G, Zhong H, Huang X, Miller S, Hegde LG, Marsteller DA, Marzabadi MR, Papp M, Overstreet DH, Gerald CP, Craig DA. The novel neuropeptide Y Y5 receptor antagonist Lu AA33810 [N-[[trans-4-[(4, 5-dihydro[1]benzothiepino[5, 4-d]thiazol-2-yl)amino]cyclohexyl]methyl]-methanesulfonamide] exerts anxiolytic- and antidepressant-like effects in rat models of stress sensitivity. J. Pharmacol. Exp. Ther. 2009; 328: 900-911.
112. Doods H, Gaida W, Wieland HA, Dollinger H, Schnorrenberg G, Esser F, Engel W, Eberlein W, Rudolf K. BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist. Eur. J. Pharmacol. 1999; 384: R3-R5.
113. Bhisikar SM, Kokare DM, Nakhate KT, Chopde CT, Subhedar NK. Tolerance to ethanol sedation and withdrawal hyper-excitability is mediated via neuropeptide Y Y1 and Y5 receptors. Life Sci. 2009; 85: 765-772.
114. Kempná P, Körner M, Waser B, Hofer G, Nuoffer JM, Reubi JC, Flück CE. Neuropeptide Y modulates steroid production of human adrenal H295R cells through Y1 receptors. Mol. Cell. Endocrinol. 2010; 314: 101-109.
115. Leslie CP, Di Fabio R, Bonetti F, Borriello M, Braggio S, Dal Forno G, Donati D, Falchi A, Ghirlanda D, Giovannini R, Pavone F, Pecunioso A, Pentassuglia G, Pizzi DA, Rumboldt G, Stasi L. Novel carbazole derivatives as NPY Y1 antagonists. Bioorg. Med. Chem. Lett. 2007; 17: 1043-1046.
116. Kameda M, Ando M, Nakama C, Kobayashi K, Kawamoto H, Ito S, Suzuki T, Tani T, Ozaki S, Tokita S, Sato N. Synthesis and evaluation of a series of 2, 4-diaminopyridine derivatives as potential positron emission tomography tracers for neuropeptide Y Y1 receptors. Bioorg. Med. Chem. Lett. 2009; 19: 5124-5127.
117. Kameda M, Kobayashi K, Ito H, Miyazoe H, Tsujino T, Nakama C, Kawamoto H, Ando M, Ito S, Suzuki T, Kanno T, Tanaka T, Tahara Y, Tani T, Tanaka S, Tokita S, Sato N. Optimization of a series of 2, 4-diaminopyridines as neuropeptide Y Y1 receptor antagonists with reduced hERG activity. Bioorg. Med. Chem. Lett. 2009; 19: 4325-4329.
118. Smith-White MA, Hardy TA, Brock JA, Potter EK. Effects of a selective neuropeptide Y Y2 receptor antagonist, BIIE0246, on Y2 receptors at peripheral neuroeffector junctions. Br. J. Pharmacol. 2001; 132: 861-868.
119. Bacchi F, Mathe AA, Jimenez P, Stasi L, Arban R, Gerrard P, Caberlotto L. Anxiolytic-like effect of the selective neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze. Peptides 2006; 27: 3202-3207.
120. Dautzenberg FM, Neysari S. Irreversible binding kinetics of neuropeptide Y ligands to Y2 but not to Y1 and Y5 receptors. Pharmacology 2005; 75: 21-29.
121. Brothers SP, Saldanha SA, Spicer TP, Cameron M, Mercer BA, Chase P, McDonald P, Wahlestedt C, Hodder PS. Selective and brain penetrant neuropeptide Y Y2 receptor antagonists discovered by whole-cell high-throughput screening. Mol. Pharmacol. 2010; 77: 46-57.
122. Jablonowski JA, Chai W, Li X, Rudolph DA, Murray WV, Youngman MA, Dax SL, Nepomuceno D, Bonaventure P, Lovenberg TW, Carruthers NI. Novel non-peptidic neuropeptide Y Y2 receptor antagonists. Bioorg. Med. Chem. Lett. 2004; 14: 1239-1242.
123. Lunniss GE, Barnes AA, Barton N, Biagetti M, Bianchi F, Blowers SM, Caberlotto L, Emmons A, Holmes IP, Montanari D, Norris R, Walters DJ, Watson SP. The identification and optimisation of novel and selective diamide neuropeptide Y Y2 receptor antagonists. Bioorg. Med. Chem. Lett. 2009; 19: 4022-4025.
124. Weinsier RL, Hunter GR, Heini AF, Goran MI, Sell SM. The etiology of obesity: relative contribution of metabolic factors, diet, and physical activity. Am. J. Med. 1998; 105: 145-150.
125. Klein S. Long-term pharmacotherapy for obesity. Obes. Res. 2004; 12: 163S-166S.
126. Fekete C, Sarkar S, Rand WM, Harney JW, Emerson CH, Bianco AC, Beck-Sickinger A, Lechan RM. Neuropeptide Y1 and Y5 receptors mediate the effects of neuropeptide Y on the hypothalamic-pituitary-thyroid axis. Endocrinology 2002; 143: 4513-4519.
127. Lecklin A, Lundell I, Paananen L, Wikberg JE, Mannisto PT, Larhammar D. Receptor subtypes Y1 and Y5 mediate neuropeptide Y induced feeding in the guinea-pig. Br. J. Pharmacol. 2002; 135: 2029-2037.
128. Polidori C, Ciccocioppo R, Regoli D, Massi M. Neuropeptide Y receptor(s) mediating feeding in the rat: characterization with antagonists. Peptides 2000; 21: 29-35.
129. Mashiko S, Ishihara A, Iwaasa H, Moriya R, Kitazawa H, Mitobe Y, Ito J, Gomori A, Matsushita H, Takahashi T, MacNeil DJ, Van der Ploeg LH, Fukami T, Kanatani A. Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine. Obesity (Silver Spring) 2008; 16: 1510-1515.
130. Ogino Y, Ohtake N, Nagae Y, Matsuda K, Moriya M, Suga T, Ishikawa M, Kanesaka M, Mitobe Y, Ito J, Kanno T, Ishihara A, Iwaasa H, Ohe T, Kanatani A, Fukami T. Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-oxospiro[isobenzofuran-1(3H), 4'-piperidin]-1'-yl}benzimidazole derivatives. Bioorg. Med. Chem. Lett. 2008; 18: 5010-5014.
131. Li G, Stamford AW, Huang Y, Cheng KC, Cook J, Farley C, Gao J, Ghibaudi L, Greenlee WJ, Guzzi M, van Heek M, Hwa JJ, Kelly J, Mullins D, Parker EM, Wainhaus S, Zhang X. Discovery of novel orally active ureido NPY Y5 receptor antagonists. Bioorg. Med. Chem. Lett. 2008; 18: 1146-1150.
132. Sakamoto T, Moriya M, Tsuge H, Takahashi T, Haga Y, Nonoshita K, Okamoto O, Takahashi H, Sakuraba A, Hirohashi T, Shibata T, Kanno T, Ito J, Iwaasa H, Gomori A, Ishihara A, Fukuroda T, Kanatani A, Fukami T. Novel orally active NPY Y5 receptor antagonists: synthesis and structure-activity relationship of spiroindoline class compounds. Bioorg. Med. Chem. 2009; 17: 5015-5026.
133. Mullins D, Adham N, Hesk D, Wu Y, Kelly J, Huang Y, Guzzi M, Zhang X, McCombie S, Stamford A, Parker E. Identification and characterization of pseudoirreversible nonpeptide antagonists of the neuropeptide Y Y5 receptor and development of a novel Y5-selective radioligand. Eur. J. Pharmacol. 2008; 601: 1-7.
134. Degen L, Oesch S, Casanova M, Graf S, Ketterer S, Drewe J, Beglinger C. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 2005; 129: 1430-1436.
135. Bellmann-Sickert K, Beck-Sickinger AG. Peptide drugs to target G protein-coupled receptors. Trends Pharmacol. Sci. 2010; 31: 434-441.
136. Pedersen SL, Sasikumar PG, Chelur S, Holst B, Artmann A, Jensen KJ, Vrang N. Peptide hormone isoforms: N-terminally branched PYY3-36 isoforms give improved lipid and fat-cell metabolism in diet-induced obese mice. J. Pept. Sci. 2010; 16: 664-673.
137. Sato N, Ogino Y, Mashiko S, Ando M. Modulation of neuropeptide Y receptors for the treatment of obesity. Expert Opin. Ther. Pat. 2009; 19: 1401-1415.
138. Moriya R, Mashiko S, Ishihara A, Takahashi T, Murai T, Ito J, Mitobe Y, Oda Z, Iwaasa H, Takehiro F, Kanatani A. Comparison of independent and combined chronic anti-obese effects of NPY Y2 receptor agonist, PYY(3-36), and NPY Y5 receptor antagonist in diet-induced obese mice. Peptides 2009; 30: 1318-1322.
139. Mashiko S, Moriya R, Ishihara A, Gomori A, Matsushita H, Egashira S, Iwaasa H, Takahashi T, Haga Y, Fukami T, Kanatani A. Synergistic interaction between neuropeptide Y1 and Y5 receptor pathways in regulation of energy homeostasis. Eur. J. Pharmacol. 2009; 615: 113-117.
140. MacNeil DJ. NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs. Curr. Top. Med. Chem. 2007; 7: 1721-1733.
141. Körner M, Reubi JC. Neuropeptide Y receptors in primary human brain tumors: overexpression in high-grade tumors. J. Neuropathol. Exp. Neurol. 2008; 67: 741-749.
142. Körner M, Waser B, Reubi JC. High expression of neuropeptide Y1 receptors in ewing sarcoma tumors. Clin. Cancer Res. 2008; 14: 5043-5049.
143. 1-Mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res. 2001; 61: 4636-4641.
144. Ruscica M, Dozio E, Motta M, Magni P. Role of neuropeptide Y and its receptors in the progression of endocrine-related cancer. Peptides 2007; 28: 426-434.
145. Lu C, Everhart L, Tilan J, Kuo L, Sun CC, Munivenkatappa RB, Jonsson-Rylander AC, Sun J, Kuan-Celarier A, Li L, Abe K, Zukowska Z, Toretsky JA, Kitlinska J. Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy. Oncogene 2010; 29: 5630-5642.
146. Cox HM, Tough IR, Zandvliet DW, Holliday ND. Constitutive neuropeptide Y Y(4) receptor expression in human colonic adenocarcinoma cell lines. Br. J. Pharmacol. 2001; 132: 345-353.
147. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev. 2003; 24: 389-427.
148. Langer M, Kratz F, Rothen-Rutishauser B, Wunderli-Allenspach H, Beck-Sickinger AG. Novel peptide conjugates for tumor-specific chemotherapy. J. Med. Chem. 2001; 44: 1341-1348.
149. 99mTc-labeled neuropeptide Y analogues as potential tumor imaging agents. Bioconjug. Chem. 2001; 12: 1028-1034.
150. Khan IU, Zwanziger D, Böhme I, Javed M, Naseer H, Hyder SW, Beck-Sickinger AG. Breast-cancer diagnosis by neuropeptide Y analogues: from synthesis to clinical application. Angew. Chem. Int. Ed. Engl. 2010; 49: 1155-1158.